Cerebrolysin for acute ischaemic stroke

Muresanu D.F. et al.

Multidimensional ensemble of outcomes in moderate-severe TBI; modest but consistent benefit on the composite endpoint at 90 days. Methodologically unusual primary analysis — the authors essentially pooled scales to get power. Read as suggestive, not definitive.

Poon W. et al.

CAPTAIN I — the Asian-Pacific companion to CAPTAIN II in moderate-to-severe TBI. Similar multidimensional analytic approach, similar directional benefit, similar sample-size limitation. Take the two CAPTAIN trials together as the modern cerebrolysin TBI dataset.

Cui S. et al.

The other Cochrane verdict — in vascular dementia, IV cerebrolysin courses improved cognition and global function with no adverse-event signal. A friendlier read than the stroke review; sample sizes still modest and follow-up short.

Medvedeva E.V. et al.

One of the few semax papers in an indexed English-language journal. Rat focal-ischemia model with a respectable transcriptomic readout — immune and vascular gene programs shift. Preclinical only; the Russian clinical literature on semax has not been replicated in Western trials.